Top

Published in:

01-07-2002 | Leading Article

Prevention of Otitis Media by Vaccination

Authors: Fiona Russell, Professor Kim Mulholland

Published in: Drugs | Issue 10/2002

Abstract

Otitis media (OM) is one of the commonest infections in childhood and a frequent reason for prescribing antibacterials in infancy. However, the increase in prevalence of antibacterial-resistant respiratory bacterial pathogens has not been matched by the development of new antibacterial agents. Bacterial vaccine strategies aim to prevent OM directly and to reduce nasopharyngeal carriage of pneumococci, thereby reducing the likelihood of developing acute OM. Complete protection against OM would require an approach targeting both bacterial and viral agents.

Immunisation with a pneumococcal conjugate vaccine provides protection against acute OM caused by pneumococcal serotypes included in the vaccine, reduces serotype-specific pneumococcal carriage, and reduces carriage of penicillin-resistant pneumococci. However, an increase in non-vaccine serotype OM has been observed in vaccinated children, which may limit the overall effectiveness of this vaccine. New vaccines targeting non-typablc Haemophilus influenzae and Mycoplasma catarrhalis are in the early stages of development. Efficacy studies with influenza vaccine have shown the most promising results to date in terms of overall reduction in OM episodes.

A more substantial reduction in the burden of OM in childhood would require a combination of vaccines that are effective against the bacterial and viral pathogens involved and that can be administered early in infancy.

Nelson WI, Kennedy DL, Lao CS, et al. Out-patient systemic anti-infective use by children in the United States: 1977 to 1986. Pediatr Infect Dis J 1988; 7: 505–9PubMedCrossRef

Vernon-Feagans L. Impact of otitis media on speech, language, cognition, and behaviour. In: Rosenfeld RM, Bluestone CD, editors. Evidence-based otitis media. Hamilton (ON): Decker, 1999: 353–73

Gates G. Cost-effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 1996; 4: 525–30CrossRef

Paradise JL, Rockette HE, Colborn DK, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99(3): 318–33PubMedCrossRef

Owen MJ, Baldwin CD, Swank PR, et al. Relation of infant feeding practices, cigarette smoke exposure, and group child care to the onset and duration of otitis media with effusion in the first two years of life. J Pediatr 1993; 123(5): 702–11PubMedCrossRef

Berman S. Otitis media in developing countries. Pediatrics 1995; 96: 126–31PubMed

Leach AJ, Boswell JB, Asche V, et al. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr Infect Dis J 1994; 13(11): 983–9PubMedCrossRef

Giebink GS. The microbiology of otitis media. Pediatr Infect Dis J 1989; 8 (1 Suppl.): S18-20

Ruuskanen O, Arola M, Hekkinen T, et al. Viruses in acute otitis media: increasing evidence for clinical significance. Pediatr Infect Dis J 1991; 10(6): 425–7PubMedCrossRef

10.

Teele DW, Klein JO, Bratton L, et al. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. The Greater Boston Collaborative Otitis Media Study Group. Rev Infect Dis 1981; 3 Suppl. 3: S113-8

11.

Makela PH, Leinonen M, Pukander J, et al. A study of the pneumococcal vaccine in prevention of clinically acute atttacks of recurrent otitis media. Rev Infect Dis 1981; 3 Suppl. 3: S124-32

12.

Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial poly-saccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 1993; 123(5): 801–10PubMedCrossRef

13.

Shahid NS, Steinhoff MC, Hoque SS, et al. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet 1995; 346(8985): 1252–7PubMedCrossRef

14.

O’Dempsey TJ, McArdle T, Ceesay SJ, et al. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 1996; 14(10): 963–70PubMedCrossRef

15.

Englund JA, Glezen WP. Passive immunization for the prevention of otitis media. Vaccine 2000; 19 Suppl. 1: S116-21

16.

Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 3: 187–95

17.

Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344(6): 403–9PubMedCrossRef

18.

Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis 1997; 175(6): 1440–5

19.

Klugman KP, Friedland IR. Antibiotic-resistant pneumococci in pediatric disease. Microb Drug Resist 1995; 1(1): 5–8PubMedCrossRef

20.

Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 2000; 356(9237): 1210–1PubMedCrossRef

21.

Obaro SK, Adegbola RA, Banya WA, et al. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348(9022): 271–2PubMedCrossRef

22.

Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180(4): 1171–6PubMedCrossRef

23.

Dagan R. Treatment of acute otitis media: challenges in the era of antibiotic resistance. Vaccine 2000; 19 Suppl. 1: S9-S16

24.

White P, Hermansson A, Svanborg C, et al. Effects of active immunisation with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media. ORL J Otorhinolaryngol Relat Spec 1999; 61: 206–11PubMedCrossRef

25.

Briles DE, Hollingshead S, Brooks-Walter A, et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000; 18(16): 1707–11PubMedCrossRef

26.

Ogunniyi AD, Folland RL, Briles DE, et al. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 2000; 68(5): 3028–33PubMedCrossRef

27.

Briles DE, Hollingshead SK, Nabors GS, et al. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2000; 19 Suppl. 1: S87-95

28.

The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3 Pt 1): 531–7CrossRef

29.

Clements DA, Langdon L, Bland C, et al. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995; 149(10): 1113–7PubMedCrossRef

30.

Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338(20): 1405–12PubMedCrossRef

Title: Prevention of Otitis Media by Vaccination
Authors: Fiona Russell
Professor Kim Mulholland
Publication date: 01-07-2002
Publisher: Springer International Publishing
Published in: Drugs / Issue 10/2002
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200262100-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevention of Otitis Media by Vaccination

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2002

Management Issues in Syphilis

Rizatriptan

Food-Drug Interactions

Metabolic and Additional Vascular Effects of Thiazolidinediones

Esomeprazole

Angiotensin II Receptor Antagonists in Chronic Heart Failure